News from berg A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 13, 2020, 14:25 ET BERG Named Visionary in Frost & Sullivan's First-Ever Frost Radar™ AI in Drug Discovery Report in the Pharmaceutical Industry

BERG, a clinical-stage biotech company that uses artificial intelligence (AI) to research diseases and develop innovative treatments, has been...

Jan 24, 2020, 18:52 ET BERG Presents Initial Clinical Data And Identification Of Response Biomarkers In A Phase 2 Pancreatic Cancer Trial Guided By Using The Interrogative Biology® Platform At ASCO-GI Meeting

BERG, a biopharmaceutical company that merges biology with technology to map and identify drivers of diseases, today announced the presentation of...

Nov 08, 2019, 07:00 ET BERG Presents Data Demonstrating That BPM31510 Promotes Cytotoxic T-cell Function And Influences Checkpoint Receptor Expression Patterns To Potentially Synergize Anti-Cancer Effect In Combination With I/O Therapies

BERG, a clinical stage biopharmaceutical company that uses artificial intelligence (AI) to discover the underlying biology of disease, today...

Oct 22, 2019, 14:51 ET BERG Collaboration Identifies Novel Mechanism Of Action Of Redox Regulation By BPM 31510 In Models Of Glioblastoma

BERG, the clinical stage biopharmaceutical company that uses artificial intelligence (AI) to discover the biology of underlying disease, today...

Sep 30, 2019, 10:22 ET BERG präsentiert neuartige Daten auf Basis seiner Bayes'schen, KI-gestützten Interrogative Biology®-Technologie, um die zugrundeliegende Biologie des Patientenansprechens in Studie zu BPM31510 bei fortgeschrittenen soliden Tumoren zu kartieren

BERG, ein auf klinischer Stufe aktives Biopharma-Unternehmen, das mithilfe von künstlicher Intelligenz (KI) und Multi-Omik neuartige biologische...

Sep 30, 2019, 10:17 ET BERG présente des données uniques en leur genre en utilisant sa technologie bayésienne basée sur l'IA, Interrogative Biology®, pour cartographier la biologie sous-jacente émanant des réactions des patients dans le cadre d'un essai avancé du BPM31510 sur les tumeurs solides

BERG, une société biopharmaceutique de stade clinique qui utilise l'intelligence artificielle (IA) et la multi-omique pour identifier de nouvelles...

Sep 30, 2019, 08:32 ET BERG presenta los primeros datos obtenidos por medio de su tecnología bayesiana con IA Interrogative Biology®

- BERG presenta los primeros datos obtenidos por medio de su tecnología bayesiana con IA Interrogative Biology® para trazar la biología subyacente de ...

Sep 28, 2019, 06:00 ET BERG Presents First-In-Kind Data Using Its Bayesian AI-Driven Interrogative Biology® Technology To Map Underlying Biology Of Patient Responses In Advanced Solid Tumor Trial Of BPM31510

BERG, a clinical stage biopharmaceutical company that utilizes artificial intelligence (AI) and multi-omics to identify novel biology and disease...

Jun 03, 2019, 11:29 ET BERG Presents Key Findings From Two Important Clinical Initiatives At The 2019 ASCO Annual Meeting: BERG's Final Phase 1 Results For BPM 31543 In Chemotherapy-Induced Alopecia And A Clinical Study Using BERG's Interrogative Biology® Platform Demonstrating The Importance Of Altruism In Pancreatic Cancer Biomarker Discovery

BERG, a biopharmaceutical company that merges biology with technology to map and identify drivers of diseases, today announced the presentation...

Apr 01, 2019, 07:30 ET BERG Presents Novel Mechanism Underlying BPM 31510 in Glioblastoma and Identification of Prostate and Pancreatic Cancer Biomarkers at 2019 AACR Meeting

BERG, a biopharmaceutical company, that combines biology and technology to discover novel biology underlying disease, today announced four...

Nov 07, 2018, 18:43 ET BERG Presents Clinical Target Validation Data for the Treatment of Parkinson's Disease and Novel Mechanism of Action in Neurological Disorders at Neuroscience 2018

BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced four abstracts...

Nov 02, 2018, 07:04 ET Berg Analytics to Present at the AMIA 2018 Annual Symposium

Berg Analytics, a division of BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases,...

Oct 25, 2018, 13:39 ET BERG Presents New Research Using AI and Multi-Omics Toward Identification of Multiple Clinical Outcome Biomarkers for Systemic Lupus Erythematosus at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting

BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, yesterday presented findings...

Oct 25, 2018, 12:30 ET BERG Presents New Research Using AI and Multi-Omics Toward Identification of Multiple Clinical Outcome Biomarkers for Systemic Lupus Erythematosus at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting

BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, yesterday presented findings...

Oct 19, 2018, 18:49 ET BERG to Present New Data Describing Details on Progress of its Oncology Portfolio and Precision Medicine Applications at the European Society for Medical Oncology 2018 Congress

BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the...

Jun 04, 2018, 04:53 ET BERG Showcases New Clinical Data on BPM 31510 at ASCO 2018

BERG, LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today presented in a poster...

May 23, 2018, 07:34 ET BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa

BERG, LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced that the U.S....

Apr 17, 2018, 08:16 ET BERG Announces Data Presentations at AACR 2018 Validating Novel Prostate Cancer Biomarkers and Clinical Activity of BPM 31510 Across Several Metabolic Cancer Types

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the presentation of 10 abstracts ...

Apr 04, 2018, 02:00 ET BERG Announces the Dosing of First UK Patient in Phase II Combination Trial of BPM 31510 and Gemcitabine for Patients with Pancreatic Cancer

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the dosing of the first patient...

Jan 22, 2018, 09:00 ET BERG Announces FDA Orphan-Drug Designation of BPM31510 for the Treatment of Pancreatic Cancer

BERG, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the U.S. Food and...

Dec 13, 2017, 08:00 ET New Research Partnership will Leverage BERG Interrogative Biology® Platform and Identify Novel Biomarker and Targets for Diagnosis and Treatment of Alzheimer's Disease

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, Massachusetts General Hospital (MGH), and...

Oct 30, 2017, 09:00 ET BERG Enters Into an Agreement With Sanofi Pasteur to Identify Biomarkers of Flu Vaccine Performance

BERG, a biopharmaceutical company that merges biology with technology, today announced a new research effort with Sanofi Pasteur, the influenza...

Oct 27, 2017, 09:00 ET BERG Honored with Partner in Progress Award from DEBRA of America at Annual Benefit for Rare Disease Epidermolysis Bullosa (EB)

BERG, a biopharmaceutical company that merges biology with technology, today announced that the Company was honored with a Partners in Progress Award ...

Sep 19, 2017, 08:00 ET BERG Broadens Relationship With The Department Of Defense (DoD) Center For Prostate Disease Research With New Predictive Biomarker Test For Prostate Cancer

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the completion of clinical...

Sep 11, 2017, 09:00 ET BERG Presents Key Clinical Data at ESMO 2017 on BPM 31510 for Advanced Pancreatic Cancer Patients and BPM 31543 for Preventing Hair-Loss in Patients Treated With Chemotherapy

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced two poster presentations showing ...